Bisphosphonates in development for metabolic bone disease

References

• FRANCIS MD, CENTER RI: The development of diphos-phonates as significant health care products. J. Chem. Educ. (1978) 55:760–766.
   Web of Science ®Google Scholar
• FRANCIS MD, MARTODAM RR: Chemical, biochemical, and medicinal properties of the diphosphonates. In: The Role of Phosphonates in Living Systems. Hilderbrand RI (Ed). Boca Raton, FL: CRC Press Inc.; 1983:55–96.
   Google Scholar
• FLEISCH H: Diphosphonates: History and mechanisms of action. Metab Bone Dis. Rel. Res. (1981) 3:279-287.Good overview of history and early work on bisphosphonates.
   Google Scholar
• FLEISCH H, RUSSELL RGG, BISAZ S, CASEY PA, MUHL-BAUER RC: The influence of pyrophosphate analogs (diphosphonates) on the precipitation and dissolution of calcium phosphate in vitro and in vivo. Calcif. Tissue Res. (1968) 2 (sup pl.) :10-10A.
   Google Scholar
• HANNUNLEMI R, LAUREN L, PUOLIJOKI H: Clodronate: An effective agent for the treatment of increased bone resorption. Drugs Today (1990) 26:375-390. Very comprehensive review of data on clodronate.
   Google Scholar
• BRELIERE JC, EMONDS-ALT X, GARCIA G: Anti-inflamma-tory products derived from methylene diphosphonic acid and process for their preparation. United States Patent No. 4,876,248; (October 24) 1989.
   Google Scholar
• ANONYMOUS: US launch for Ticlid soon. Scrip (1991)1675: 23.
   Google Scholar
• STAHL P, SCHMITZ B: Crystalline disoclium 3-amino-l-hydroxypropane-1,1-diphosphonate pentahydrate. United States Patent No. 4,711,880; (December 8) 1987.
   Google Scholar
• ROSINI S, STAIBANO G: Pharmacologically active bisphosphonates, process for the preparation thereof and pharmaceutical compositions therefrom. United States Patent No. 4,621,077; (November 4) 1986.
   Google Scholar
• ANONYMOUS. Japanese product news in brief. Marketlet-wr (1992) 19:22.
   Google Scholar
• SUNBERG RJ, EBETINO FH, MOSHER CT, ROOF CF: Dc- signing drugs for stronger bones. Chem. Tech. (1991) 21:304–309.
   Google Scholar
• A very good review of the varying bone affinities in the phosphonoal-kyl phosphinate class of analogues.
   Google Scholar
• BENEDICT JJ, PERKINS CM: Pharmaceutical composi-tions containing geminal diphosphonates. European Patent Application, Publication No. 186–405; (March 6) 1991.
   Google Scholar
• FRANCIS MD, HOVANCIK K, BOYCE RW: NE-58095: A diphosphonate which prevents bone erosion and pre-serves joint architecture in experimental arthritis. Int. J. Tissue React. (1989) 11:239–252.
   PubMedGoogle Scholar
• This is one of the best papers on the effects of a bisphosphonate in experimental arthritis. It includes colour pictures of histological sections.
   Google Scholar
• ANONYMOUS: YM-175. Drugs Future (1992) 17:293–296.
   Google Scholar
• ANONYMOUS: Yamanouchi reorganizes in Europe. Scrip (1991) 1676:14,
   Google Scholar
• ANONYMOUS: Japanese market for osteoporosis drugs.Marketletter (1991) 18:21.
   Google Scholar
• ANONYMOUS: In Brief (Products): Yamanouchi Phar-maceutical's potential osteoporosis treatment YM-175. Marketletter (1991) 18:28.
   Google Scholar
• ANONYMOUS: RPR/B-Mannheku bisphosphonate deal.Scrip (1993) 1691:10.
   Google Scholar
• GREEN JR, JAEGI KA, MUELLER K: Pharmacological pro-file of CGP-42,446: Anew, highly potent, anti-osteolytic bisphosphonate. J. Bone Min. Res. (1994) 9:745–752.
   PubMed Web of Science ®Google Scholar
• FLEISCH H, RUSSELL RGG, FRANCIS MD: Diphosphonatesinhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science (1969) 165:1262–1264.
   PubMed Web of Science ®Google Scholar
• FRANCIS MD, RUSSELL RGG, FLEISCH H: Diphosphonatesinhibit formation of caMum phosphate crystals in vitro and pathological calcification in vivo. Science (1969) 165:1264–1266.
   PubMed Web of Science ®Google Scholar
• EBETINO FH: Methylene phosphortoalkylphosphi-nates, pharmaceutical compositions, and method for treating abnormal calcium and phosphate metabolism. European Patent Application, Publication No. 298553; (Janu-ary 11) 1989.
   Google Scholar
• IBBOTSON KJ, D'SOUZA SM, BAYLESS A, EBRAHIMPOURA, EBETINO FH, WOODIEL FN, FALL PE, RAISZ LG: The phosphonate moieties of bisphosphonates are more than just a targeting function: evidence from the study of bisphosphonates analogues in vitro. Bone and Miner. (suppl. 1), S1-S92, S66
   Google Scholar
• EBETINO FH, BAYLESS AV, DANSEREAU SM: Phosphono-carboxylate compounds for treating abnormal calcium and phosphate metabolism. European Patent Publication No. 9324131, 1994.
   Google Scholar
• SCHENK R, EGGLI P, FLEISCH H, ROSINI S: Quantitative morphometric evaluation of the inhibitory activity ofnew aminobisphosphonates on bone resorption in the rat. CalV. Tissue Int. (1986) 38:342–349.
   PubMed Web of Science ®Google Scholar
• Landmark paper examining the histologic response to antiresorptive bisphosphonates.
   Google Scholar
• SIETSEMA WK, EBETINO FH, SALVAGNO AM, BEVAN JA: Antiresorptive dose-response relationships acrossthree generations of bisphosphonates. Drugs Exp. Clin. Res. (1989) 15:389–396–
   Google Scholar
• This paper outlines structure-activity discoveries and how they were made temporally.
   Google Scholar
• TAKEUCHI M, SAKAMOTO S, YOSHIDA M, ABE T, AND ISOMURA Y: Studies on novel bone resorption inhibi-tors. L Synthesis and pharmacological activities of aminomethylenebisphosphonate derivatives. Chem. Pharm. Bulk (1993) 41:688–693.
   Google Scholar
• The best review, to date, of YM175 chemistry and its analogues.
   Google Scholar
• MUHLBAUER RC, BAUSS F, SCHENK R, ETAL.: BM-21.0955,a potent new bisphosphonate to inhibit resorption. J. Bone Miner. Res. (1991) 6:1003–1011.
   Google Scholar
• EBETINO FH, DANSEREAU SM: Bisphosphonates: Struc-ture activity relationships and therapeutic implica-tions. In: Bisphosphonate Therapy in Acute and Chronic Bone LOSS. Bijvoet OLM, Canfield R, Fleisch H, Russell RGG (Eds.). Elsevier, Amsterdam (In press).
   Google Scholar
• POWELL JH, DEMARK BR: Clinical pharmacokinetics of diphosphonates. In: Bone Resorption, Metastasis, and Diphosphonates. Monographs of the Mario Negri Institute for Pharmacological Research. Garattini S (Ed). New York, NY: Raven Press, 1984:41–49.
   Google Scholar
• This paper was the first to recognise the complexity of bisphosphon-ate compartmental modelling. The authors have taken data from published papers and re-analysed them using a non-compartmental approach more suited for bisphosphonte pharmacokinetics.
   Google Scholar
• YAKATAN GJ, POYNOR WJ, TALBERT RL, ET AL.: CID- dronate kinetics and bioavailabRity. Clin PharmacoL Ther. (1982) 31:402–410.
   Google Scholar
• Very comprehensive treatise of clodronate pharmacokinetics.
   Google Scholar
• PENTIKÁINEN PJ, ELOMAA I, NURMI AK, KARKKAINEN S: Pharmacokinetics of clodronate in patients with metas-tatic breast cancer. Int.J. Pharmacol. Ther. Toxicol (1989) 27:222–228.
   PubMedGoogle Scholar
• UN JH, DUGGAN DE, CHEN IW, ELLSWORTH RL: Physi-ological disposition of alendronate, a potent an-tiosteolytk bisphosphonate, in laboratory animals. Drug Metab. Dispos. (1991) 19:926–932.
   PubMed Web of Science ®Google Scholar
• GERTZ, BJ, KLINE WF, MATUSZEWSKI BK, SACCO JF, LASSETER KC, PORRAS AG: Oral bioavailability and dose proportionality of alendronate (aminohydroxy-butylidene bisphosphonate) in postmenopausal women.]. Bone Miner. Res. (1991) 6\(suppl. 1):S281.
   Google Scholar
• FOGELMAN I, SMITH L, MAZESS R, WILSON MA, BEVAN JA: Absorption of oral diphosphonate in normal subjects. Clin. Endocrinot (1986) 24:57–62.
   PubMed Web of Science ®Google Scholar
• NECCIARI J, TOUSSAIN P, FELS JP, DERBY G, LUYCKX A, SCHEEN A: Effect of food intake on kinetics and bioavail-ability of (4-chlorophenyl) thiomethylene bisphos-phonic acid. Calcif. Tissue Int. (1989) 44(suppl):S104.
   Google Scholar
• EBRAHIMPOUR A, FRANCIS MD: Physical chemical con-siderations in bisphosphonate related therapeutics. In: Bisphosphonate Therapy in Acute and Chronic Bone Loss. Bijvoet OLM, Canfield R, Fleisch H, Russell RGG (Eds.). Elsevier, Amsterdam (In press).
   Google Scholar
• HOGGARTH CR, BENNETT' R, DALEY-YATES PT: The phar- macokinetics and distribution of pamidronate for a range of doses in the mouse. Cakif. Tissue Int. (1991) 49:416–420.
   PubMed Web of Science ®Google Scholar
• A well-executed series of experiments looking at pharmacokinetics of bisphosphonates.
   Google Scholar
• MONKKONEN J, YLITALO P: The tissue distribution of dodronate (dichloromethylene bisphosphonate) in mice. Eur.J. Drug Metab . Pharmacokinet. (1990) 15:239–243.
   PubMed Web of Science ®Google Scholar
• LAUREN L, OSTERMAN T, KARHI T: Pharmacokinetics of clodronate after single intravenous, intramuscular, and subcutaneous injections in rats. Pharmacol. Toxicol (1991) 69:365–368.
   PubMedGoogle Scholar
• MICHAEL WR, KING WR, WAKIM JM: Metabolism of diso- dium ethane-1-hydroxy-1,1-diphosphonate (disodium etidronate) in the rat, rabbit, dog, and monkey. Toxicol. Appl. Pharmacol (1972) 21:503515.
   Google Scholar
• Very thorough review of etidronate metabolism in several species.
   Google Scholar
• OSTERMAN T, LAUREN L: level of clodronate in bone after single and repeated subcutaneous injections in rats. Pharmacol. Toxicol. (1991) 69:369–371.
   PubMedGoogle Scholar
• KASTING GB, FRANCIS MD: Retention of etidronate in human, dog, and rat.]. Bone Miner. Res. (1992) 7:513-522.An important paper on the theory behind accumulation of bisphos-phonate in bone tissue.
   Google Scholar
• HUGHES DE, MIAN M, GUILLAND-CUMMING DF, RUSSELL RGG: The cellular mechanism of action of bisphos-phonates. Drugs Exp. Clin. Res. (1991) 17:109–114.
   PubMedGoogle Scholar
• SATO M, GRASSER W: Effects of bisphosphonates on Isolated rat osteoclasts as examined by reflected light microscopy. Bone Miner. Res. (1990) 5:31–40.
   PubMed Web of Science ®Google Scholar
• GEDDES AD, D'SOUZA SM, EBETINO FH, IBBOTSON KJ: Bisphosphonates: structure-activity relationships and therapeutic implications. Reprint in: Bone and Mineral Research 1994. A regular survey of developments in the field of bone and mineral metabolism. Heersche JNM, Kanis JA (Eds.). Amsterdam, 1994. Volume 8. Elsievier Science BV; 1994: 265–306.
   Google Scholar
• EBETINO FH, KAAS SM, CRAWFORD RJ: Bisphosphon- ates: Molecular modelling, structure-activity relation-ships and the rational design of new analogs. Phosphorus, Sulfur and Silicon (1993) 76:151–154.
   Web of Science ®Google Scholar
• An introduction of the structure activity data supporting a specific recognition event within the cellular mechanism of bisphosphonate antiresorptive activity.
   Google Scholar
• BOONEKAMP PM, VAN DER WEE-PALS LJA, VAN WIJK-VANLENNEP MML, THESINGH CW, BIJVOET OLM: Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix. Bone Miner (1986) 1:27–39.
   PubMedGoogle Scholar
• FLANAGAN AM, CHAMBERS TJ: Dkhloromethylene-bisphosphonate (C12MBP) inhibits bone resorption through injury to osteoclasts that resorb C12MBP-coated bone. Bone Miner. (1989) 6:33–43.
   PubMedGoogle Scholar
• ZIMOLO Z, TANAKA H, SATO M, RODAN GA: The effect of alendronate on membrane permeability to cations In osteoclast-like cells.]. Bone Miner. Res. (1991) 6\(suppl. 1):S147.
   Google Scholar
• Very novel experiments suggesting new mechanism of action.
   Google Scholar
• SAHNI M, GUENTHER, HL, FLEISCH H, COLLIN P, MARTINTJ: Bisphos phonates act on rat bone resorption through the mediation of osteoblasts. J. Clin. Invest. (1993) 91:2004–2011.
   PubMed Web of Science ®Google Scholar
• VITTE C, FLEISCH H, GUENTHER HL: Osteoblasts mediatethe bisphosphonate inhibition on bone resorption through synthesis of an osteoclast-inhibiting activity. Bone and Miner. (suppl.) S142.
   Google Scholar
• ROGERS MJ, WATTS DJ, RUSSELL RGG, JI X, XTONG 3g,BLACKBURN M, BA'YLESS AV, EBETINO FH: Inhibitory effects of bisphosphonates on growth of amoebae of the cellular slime mold dictyostelium discoideum. Bone Miner. Res. (1993) 9(7):1029–1039.
   Web of Science ®Google Scholar
• PARFITT AM: The three organizational levels of bone remodeling: Implications for the interpretation of bio-chemical markers and the mechanisms of bone loss. In: Osteoporosis 1990. Proceedings of the Third International Symposium on Osteoporosis. Christiansen C, Overgaard K (Eds.). Copenhagen, Denmark, October 14–20, 1990. Volume 1. Copenhagen, Denmark: Osteopress ApS;1990:429–434.
   Google Scholar
• Dr. Parfitt is one of the world's two most renowned histomor- phometrists. This paper contains important discussion and perspec- tive on mechanisms of bone gain/loss during remodelling.
   Google Scholar
• ERIKSEN EF: Normal and pathological remodeling of human trabecular bone: Three dimensional reconstruc- tion of the remodeling sequence in nortnals and in metabolic bone disease. Endocr. Rev. (1986) 7:379-408. Dr. Eriksen is the second of the world's two most renowned histomorphometrists. This paper outlines methods for histomor-phometric analysis of bone. Very technical.
   Google Scholar
• STEINICHE T, HASLING C, CHARLES P, ERTKSEN EF, MEL-SON F, MOSEKILDE L: The effects of etidronate on trabecular bone remodeling in postmenopausal spinal osteoporosis: A randomized study comparing intermit-tent treatment and an ADFR regime. Bone (1991) 12:155–163.
   PubMed Web of Science ®Google Scholar
• BOYCE RW, ERIKSEN EF, FRANKS AF, STOKES CL, JANK-OWSKY ML: Effect of NE-58095 on trabecular bone remodeling: 3-D reconstruction of the remodeling site. J. Bone Miner. Res. (1989) 4\(suppl. 1):S194.
   Google Scholar
• DE VERNEJOUL MC, POINTILLART A, BERGOT C, ETAL.: Different schedules of administration of (3amino-1-hy-droxypropylidene)-1,1-bisphosphonate induce differ-ent changes in bone remodeling. Calcif. Tissue Int. (1987) 40:160–165.
   Google Scholar
• REGINSTER JY, DEROISY R, DENTS D, ETAL.: Prevention of postmenopausal bone loss by tiludronate. Lancet (1989) 2:1469–1471.
   PubMed Web of Science ®Google Scholar
• HARRIS ST, WATTS NB, JACKSON RD, ETAL.: Four-year study of intermittent cyclical etidronate treatment of postmenopausal osteoporosis: Three years of blinded therapy followed by one year of open therapy. Am. J. Med. (1993) 95:557–567.
   Google Scholar
• CHRISTIANSEN C, CHRISTIANSEN MS, TRANSBOL I: Bone mass in postmenopausal women after withdrawal of oestrogen/gestagen replacement therapy. Lancet (1981) 1:459–461.
   PubMed Web of Science ®Google Scholar
• This landmark paper demonstrates that oestrogen prevents the loss of bone during the postmenopausal period but that when oestrogen therapy is discontinued, bone loss will resume at the same rate as if oestrogen were never given.
   Google Scholar
• OVERGAARD K, HANSEN MA, NIELSEN VAH, RIIS BJ, CHRISTIANSEN C: Discontinuous calcitonin treatment of established osteoporosis - effects of withdrawal of treat-ment. Am. J. Med. (1990) 89:16.
   Google Scholar
• SHIOTA E, EGUCHI M, KAWAMURA H, ETAL.: Effects of long term low dose EHDP on experimental osteoporosis induced by sciatic nerve dissection in rats. Sekei Geka To Saigai Geka (1984) 32:772–776.
   Google Scholar
• SHIOTA E: Effects of diphosphonate on osteoporosis Induced in rats: Roentogenological, histological, and biomechanical studies. Fukuoka Igaku Zasshi (1985) 76:317–342.
   PubMedGoogle Scholar
• ARAI M, TOGARI A, MATSUMOTO S: Femoral mechanical properties in rat: Effects of EHDP. Jpn. J. Pharmacol. (1990) 52\(suppl 1):303P.
   Google Scholar
• GEUSENS P, NUS J, VAN DER PERRE G, ETAL.: Longitudinal skeletal effect of tiludronate on bone density and strength in monkeys. In: Osteoporosis 1990. Proceedings of the Third International Symposium on Osteoporosis. Chris-tiansen C, Overgaard K (Eds.). Copenhagen, Denmark, Oc-tober 14–20, 1990. Volume 1. Copenhagen, Denmark: Osteopress ApS; 1990:366–367.
   Google Scholar
• FERRETTI JL, COINTRY G, CAPOZZA R, MONTUORI E, ROLDAN E, PEREZ LLORET A: Biomechanical effects of the full range of useful doses of (3-amino-1-hy-droxypropylidene)-1,1-bisphosphonate (API)) on fe-mur diaphyses and cortical bone tissue in rats. Bone Miner. (1990) 11:111–122.
   PubMedGoogle Scholar
• KAWAMUKI K, ABE T, KUDO M, ETAL.: Prophylactic and therapeutic effect of YM-175 on bone loss induced by ovariectomy and immobilization in rats. J. Bone Miner. Res. (1991) 6\(suppl. 1):S214.
   Google Scholar
• FERRETI JL: Effects of bisphosphonates on bone biomechanics. In: Bisphosphonate Therapy in Acute andChronic Bone Loss. Bijvoet OLM, Canfield R, Fleisch H, Russell RGG (Eds.). Elsevier, Amsterdam (In press).
   Google Scholar
• Excellent review of biomechanics and bisphosphonates.
   Google Scholar
• FITTON A, MCTAVISH D: Pamidronate: A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs (1991) 41:289–318.
   PubMed Web of Science ®Google Scholar
• Good source of information on pamidronate.
   Google Scholar
• COLEMAN RE, DIRIX LY, DODWELL D, ETAL.: Phase I/11 evaluation of effervescent and enteric coated oral pamidronate for bone metastases. Fur. J. Cancer (1991) 27:945–946.
   Google Scholar
• FENTON AJ, GUTTERIDGE DH, KENT GN, ETAL.: Intrave-nous aminobisphosphonate in Paget's disease: Clinical, biochemical, histomorphometric and radiological re-sponses. Clin. Endocrinol. (Oxf) (1991) 34:197–204.
   Google Scholar
• HOSKING DJ: Advances in the management of Paget's disease of bone. Drugs (1990) 40:829–840.
   PubMed Web of Science ®Google Scholar
• RUSSELL RGG, SMITH R, PRESTON C, WALTON RJ, WOOD CG: Diphosphonates in Paget's disease. Lancet (1974) 1:894–898.
   PubMed Web of Science ®Google Scholar
• ALTMAN RD: Long-term follow-up of therapy with inter-mittent etidronate disodium in Paget's disease of bone. Am. J. Med. (1985) 79:583–590.
   PubMed Web of Science ®Google Scholar
• MEUNIER PJ, ALEXANDRE C, EDOUARD C, ETAL.: Effects of disodium dichloromethylene diphosphonate on Paget's disease of bone. Lancet (1979) 1:489–492.
   Google Scholar
• REGINSTER JY, JEUGMANS-HUYNEN AM, ALBERT A, ETAL.:Biological and clinical assessment of a new bisphos-phonate, (chloro-4-phenyl) thiomethylene bisphos-phonate, in the treatment of Paget's disease of bone. Bone (1988) 9:349–354.
   PubMed Web of Science ®Google Scholar
• LECART MP, REGINSTER JY, DEROISY R, ETHGEN D, SAR-LET N, FRANCHIMONT P: Treatment of Paget's disease of bone with a five day course of oral tiludronate. In: Osteoporosis 1990. Proceedings of the Third International Symposium on Osteoporosis. Christiansen C, Overgaard K (Eds.). Copenhagen, Denmark, October 14–20, 1990. Volume 1. Copenhagen, Denmark: Osteopress ApS; 1990:366–367.
   Google Scholar
• RICHARDSON PC, CANTRILL JA, ANDERSON DC: Experi-ence of treating 218 patients with Paget's disease of bone using intravenous 3-aminohydroxypropylidene-1,1-bisphosphonate. In: Calcium Regulation, and Bone Metabolism. Basic and Clinical Aspects. Cohn DV, Glorieux FH, Martin TJ (Eds.). Volume 10. Amsterdam: Excerpta Medica; 1990:509–514.
   Google Scholar
• HEYNEN G, DELWAIDE P, B1JVOET OLM, FRANCHIMONTP: Clinical and biological effects of low doses of 3-amino-1-hydroxypropylidene-1,1-bisphosphonate (APD) in Paget's disease of bone. Eur.J. Clin. Invest. (1982) 11:29–35.
   Google Scholar
• O'DOHERTY DP, BICICERSTAFF DR, MCCLOSKEY EV, ETAL: Treatment of Paget's disease of bone with amino-hydroxybutylidene bisphosphonate. J. Bone Miner. Res. (1990) 5:483–491.
   PubMed Web of Science ®Google Scholar
• KYLSTRA JW, BEK10ER PJ, CLEMENS11, VALENTIN-OPRANA, AXELROD DW, SINGER FR: Risedronate in resistant Paget's disease of bone. Bone Miner. (1992) 17\(suppl. 1):209.
   Google Scholar
• HOROWITZ E, MILLER JL, ROSE LI: Etidronate for hyper-calcemia of malignancy and osteoporosis. Am. Fam. Physician (1991) 43:2155–2159.
   PubMed Web of Science ®Google Scholar
• FLEISCH H: Bisphosphonates. Pharmacology and use in the treatment of tumor-induced hypercalcaemic and metastatic bone disease. Drugs (1991) 42:919–944.
   PubMed Web of Science ®Google Scholar
• SINGER FR, FERNANDEZ M: Therapy of hypercakernia of malignancy. Am. J. Med. (1987) 82(suppl. 2A):34–41.
   Google Scholar
• JACOBS TP, GORDON AC, SILVERBERG SJ, ET AL.: Neoplas-tic hypercakemia: Physiologic response to intravenous etidronate disodium. Am.J. Med. (1987) 82(suppl. 2A):42–50.
   Google Scholar
• BONJOUR JP, RIZZOLI R: Treatment of hypercalcemia ofmalignancy with clodronate. Bone (1991) 12\(suppl. 1):S19–S23.
   Google Scholar
• ADAMI S, BOLZICCO GP, RIZZO A, ET AL.: The use ofdichloromethylene bisphosphonate and aminobutane bisphosphonate In hypercalcemia of malignancy. Bone Miner. (1987) 2:395–404.
   Google Scholar
• RALSTON SI-I, DRYBURGH FJ, COWAN RA, GARDNER MD,JENKINS AS, BOYLE IT: Comparison of aminohy-droxypropylidene diphosphonate, mithrarnycin, and corticosteroids/calcitonin in treatment of cancer asso-ciated hypercalcemia. Lancet (1985) 2:907–910.
   PubMed Web of Science ®Google Scholar
• DARAGON A, PEYRON R, SERRURIER D, DESHAYES P: Treatment of hypercalcemia of malignancy with intra-venous aminohydroxypropylidene bisphosphonate. Current Ther. Res. (1991) 50:10–21.
   Web of Science ®Google Scholar
• BICKERSTAFF DR, O'DOHERTY DP, MCCLOSKEY EV, HAMDY NAT, MIAN M, KANIS JA: Effects of ami-nobutylidene diphosphonate in hypercalcemia due to malignancy. Bone (1991) 12:17–20.
   PubMed Web of Science ®Google Scholar
• KAWAMURA J, TOCHIGI H, YANAGAWA M, ET AL.: Effects of etidronate disodium (EHDP) on urogenital malignan-cies with bone metastases: A muhicentered collabora-tive evaluation. Hinyokika Kiyo (1988) 34:528–537.
   Google Scholar
• ATTARDO-PARRINELLO G, MERLINI G, PAVESI F, CREMA F, FIORENTINI ML, ASCARI E: Effects of a new amino-diphosphonate (aminohydroxybutylidene diphos-phonate) in patients with osteolytic lesions from metastases and myelomatosis: Comparison with di-- chloromethylene diphosphonate. Arch. Intern. Med. (1987) 147:1629–1633.
   PubMed Web of Science ®Google Scholar
• COLEMAN RE, WOLL PJ, MILES M, SCRTVENER W, RUBENS RD: Treatment of bone metastases from breast cancer with (3-amino- 1-hydroxypropylidene)-1, 1-bisphos-phonate (API)). Br. J. Cancer (1988) 58:621–625.
   PubMed Web of Science ®Google Scholar
• HALL DG, STOICA G: Effect of the bisphosphonate rise-dronate on bone metastases in a rat mamamary adeno-carcinoma model system_ J. Bone Miner. Res. (1994) 9(2):221–230.
   PubMed Web of Science ®Google Scholar
• ROSS PD, DAVIS JW, EPSTEIN RS, WASNICH RD: Pre-exist-ing fractures and bone mass predict vertebral fracture incidence in women. Ann. Intern. Med. (1991) 114:919–923.
   PubMed Web of Science ®Google Scholar
• FELSON DT, ZHANG Y, HANNAN MT, KIEL DP, WILSON PWF, ANDERSON JJ: The effect of postmenopausal estro-gen therapy on bone density in elderly women. New Engl. J. Med. (1993) 329:1141–1146.
   PubMed Web of Science ®Google Scholar
• STORM T, THAMSBORG G, STEINICHE T, GENANT HK, SORENSEN OH: Effect of intermittent cyclical etidronatetherapy on bone mass and fracture rate in women with postmenopausal osteoporosis. New Engl. J. Med. (1990) 322:1265–1271.
   PubMed Web of Science ®Google Scholar
• This paper and the two following references were the first to report the fracture-reducing effects of etidronate.
   Google Scholar
• STORM T, THAMSBORG G, STEINICHE T, GENANT HK, SORENSEN OH: Etidronate for postmenopausalosteoporosis [response to letter to editor]. New Engl. J. Med. (1990) 323:1209–1210.
   PubMedGoogle Scholar
• WATTS NB, HARRIS ST, GENANT HK, ET AL.: Intermittent cyclical etidronate treatment of postmenopausalosteoporosis. New Engl. J. Med. (1990) 323:73–79.
   Google Scholar
• SHIOTA E, HAGA B, KUGA Y, ANDO T, TOMOHIRO S: Effect by the administration of HEIIP for osteoporosis. In: Osteoporosis 1990. Proceedings of the Third International Symposium on Osteoporosis. Christiansen C, Overgaard K (Eds.). Copenhagen, Denmark, October 14–20, 1990. Volume 2. Copenhagen, Denmark: Osteopress ApS; 1990:1280–1282.
   Google Scholar
• FUKUCHI M, SUMI Y: The effect of periodic therapy of HEBP (EHDP) on bone mineral density in osteoporosis. In: Osteoporosis 1990. Proceedings of the Third International Symposium on Osteoporosis. Christiansen C, Overgaard K (Eds.). Copenhagen, Denmark, October 14–20, 1990. Volume 2. Copenhagen, Denmark: Osteopress ApS; 1990:1051–1053.
   Google Scholar
• YO K, TSUJI H, TOMINAGA H, TATEISHI H: Continuous therapy using EHDP for elderly osteoporosis. Nippon Kotsutaisha Gakkai Zasshi (J. Bone Miner. Metab. Japan) (1989) 7:104.
   Google Scholar
• PAPAPOULOS SE, LANDMAN JO, BIJVOET OLM, ET AL.: The use of bisphosphonates in the treatment of osteoporosis. Bone (1992) 13:S41–S49.
   Google Scholar
• DEVOGELAER JP, HUAUX JP, NAGANT DE DEUXCHAISNES C: Bisphosphonate therapy with APD in involutional osteoporosis with vertebral crush fractures. In: Osteoporosis 1987. Proceedings of the International Sympo-sium on Osteoporosis. Christiansen C, Johansen JS, Rils BJ (Eds.). Aalborg, Denmark, September 27-October 2, 1987. Volume 2. Copenhagen, Denmark: Osteopress ApS; 1987:950–952.
   Google Scholar
• VALKEMA R, VISMANS FIFE, PAPAPOULOS SE, PAUWELS EKJ, BIJVOET OLM: Maintained improvement in calcium balance and bone mineral content in patients with osteoporosis treated with the bisphosphonate API). Bone Miner. (1989) 5:183–192.
   PubMedGoogle Scholar
• PASSER' M, BARONI MC, PEDRAZZONI M, ET AL.: Inter-mittent treatment with intravenous 4-amino-1-hy-droxybutylidene-1,1-bisphosphonate (AHBuBP) in the therapy of postmenopausal osteoporosis. Bone Miner. (1991) 15:237–247.
   PubMedGoogle Scholar
• MULDER H, STRUYS A: Intermittent cyclical etidronate in the prevention of corticosteroid-induced bone loss. Br. J. Rheumatol (1994) 33(4) 348–350.
   PubMedGoogle Scholar
• REID IR, ALEXANDER CJ, KING AR, IBBERTSON HK: Pre-vention of steroid induced osteoporosis with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (API)). Lancet (1988) 1:143–146.
   PubMed Web of Science ®Google Scholar
• ADAMI S, MIAN M, BERTOLDO F, ET AL.: Regulation of calcium parathyroid hormone feedback in primary hyperparathyroidism: Effects of bisphosphonate treat-ment. CUn. Endocr. (1990) 33:391397.
   Google Scholar
• TAN TT, ALZAID AA, SUTCLIFFE N, GARDNER MD, THOMPSON JA, BOYLE IT: Treatment of hypercalcemia In thyrotoxicosis with aminohydroxypropylidene diphosphonate. Postgrad. Med. J (1988) 64:224–227.
   PubMed Web of Science ®Google Scholar
• FRANCIS MD, FLORAL, KING WR: The effects of disodium ethane-1-hydroxy-1,1-diphosphonate in adjuvant-in-duced arthritis in rats. Calcif. Tissue Res. (1972) 9:109–121.
   PubMedGoogle Scholar
• OSTERMAN T, KIPPO K, LAUREN L: Effect of clodronate In adjuvant arthritis. J. Bone Miner. Res. (1992) 7\(suppl. 1):S289.
   Google Scholar
• BARBIER A, BRELIERE JC, REMANDET B, RONCUCCI R: Studies on the chronic phase of adjuvant arthritis: Effect of SR-41319, a new bisphosphonate. Ann. Rheum. DO. (1986) 45:67–74.
   PubMed Web of Science ®Google Scholar
• GLATT M, BLATTLER A, BISPING M, BRAY MA: Effects of diphosphonates (API), EHDP) on inflammation and bone turnover in adjuvant arthritis in rats. Expertentia (1983) 39:681.
   Google Scholar
• MARKUSSE HM, LAFEBER GJM, BREEDVELD FC: Bisphos-phonates in collagen arthritis. Rheumatol. mt. (1990) 9:281–283.
   Google Scholar
• RALSTON SH, HACKING L, WILLOCKS L, BRUCE F, PIT-KEATHLY DA: Clinical, biochemical, and radiographic effects of aminohydroxypropylidene bisphosphonate treatment in rheumatoid arthritis. Ann. Rheum. Dis. (1989) 48:396–399.
   PubMed Web of Science ®Google Scholar